摘要
目的分析特瑞普利单抗药品不良反应(ADRs)的发生规律及特点,为临床安全用药提供参考。方法检索中国学术期刊全文数据库、万方数据库、维普中文科技期刊数据库、Pub Med及Embase收载的特瑞普利单抗致ADRs的个案报道,并进行描述性分析。结果特瑞普利单抗致ADRs的文献报道有6篇,共7例患者,其中男性3例(占42.9%),女性4例(占57.1%);年龄集中在34~66岁;多发生在用药后3个月内(5例,占71.4%);ADRs以皮肤系统(3例,占42.9%)和内分泌系统(3例,占42.9%)损害为主。结论目前报道的特瑞普利单抗所致的ADRs均为免疫相关不良反应,应加强对特瑞普利单抗内分泌系统与皮肤系统的监测,尤其关注患者用药3个月内及长期用药的安全性。
AIM To analyze the occurrence and characteristics of adverse drug reactions(ADRs)of toripalimab,and to provide references for clinical safe medication.METHODS The case reports of ADRs induced by toripalimab were collected in CNKI,WANFANG,VIP,PubMed and Embase and analyzed in depth.RESULTS There were 7 cases from 6 articles of toripalimab ADRs reported in the literature,including 3 males(42.9%)and 4 females(57.1%).The age was concentrated in 34–66 years old.Most of them occurred within 3 months after treatment(5 cases,71.4%).ADRs mainly damaged skin system(3 cases,42.9%)and endocrine system(3 cases,42.9%).CONCLUSION The specific ADRs of toripalimab is immune-related adverse events.The monitoring of the endocrine system and the skin system should be strengthened,with particular attention to the safety of medication within 3 months and long-term.
作者
薛静
黎小妍
XUE Jing;LI Xiaoyan(Department of Clinical Pharmacology,The Sixth Affliated Hospital of Sun Yat-Sen University,Guangzhou 510655,China)
出处
《中国临床药学杂志》
CAS
2022年第5期375-379,共5页
Chinese Journal of Clinical Pharmacy
